美托洛尔联合阿托伐他汀钙治疗慢性心力衰竭患者的效果评价

Effect of metoprolol combined with atorvastatin calcium in patients with chronic heart failure

  • 摘要: 目的 探讨美托洛尔联合阿托伐他汀钙治疗慢性心力衰竭患者的效果。 方法 选取120例慢性心力衰竭患者,随机分为2组各60例。对照组在常规治疗基础上采用美托洛尔治疗,观察组在对照组基础上采用阿托伐他汀钙治疗。比较2组治疗前后的心功能指标变化、血浆超敏C反应蛋白(hs-CRP)水平及不良反应。 结果 观察组治疗总有效率显著高于对照组(P < 0.05)。观察组治疗后左室收缩末期内径(LVEDs)、左室舒张末期容量(EDV)低于对照组,左心室射血分数(LVEF)高于对照组,血浆hs-CRP水平低于对照组,差异均有统计学意义(P < 0.05)。2组不良反应发生率比较无显著差异(P > 0.05)。 结论 美托洛尔联合阿托伐他汀钙治疗慢性心力衰竭效果显著,可改善患者心功能,降低血浆hs-CRP水平,且无明显不良反应。

     

    Abstract: Objective To investigate the therapeutic effect of metoprolol combined with atorvastatin calcium in patients with chronic heart failure. Methods A total of 120 patients with chronic heart failure treated in our hospital were selected and randomly divided into two groups. The control group(n=60)was given metoprolol based on routine treatment, and the observation group(n=60)was treated by atorvastatin calcium treatment on the basis of the control group. Cardiac function indexes and plasma high sensitivity C reactive protein(hs-CRP)and adverse reactions before and after treatment in the two groups were compared. Results The total effective rate in the observation group was higher than that in the control group, and the difference was statistically significant(P < 0.05). After treatment, the left ventricular end-systolic diameter(LVEDs), left ventricular end-diastolic volume(EDV)in the observation group were lower than those in the control group, left ventricular ejection fraction(LVEF)was higher than that in the control group, and plasma hs-CRP was lower than that in the control group(P < 0.05). There were no differences in adverse reactions between the two groups(P > 0.05). Conclusion Metoprolol combined with atorvastatin calcium has a significant effect on chronic heart failure, with significant improvement in cardiac function and a decrease in hs-CRP, and no obvious side effects are found.

     

/

返回文章
返回